SELENOW and breast cancer: Indeed, we found that overexpression of piR-36,712 in breast cancer cells considerably decreased SEPW1 level but increased P53 and P21 levels; however, knockdown of piR-36,712 substantially increased SEPW1 levels but decreased P53 and P21 levels (Fig. 6a).